Merck (MRK +0.5%) gets a boost out of positive comments out of Barron's yesterday, saying that promising new drugs and a strong dividend should keep investors buying it for some time to come. Moreover, Barron's adds, headcount reductions and synergies from its Schering-Plough acquisition of have gone a long way towards improving the company's margin and growth outlook. Although the stock is trading near 52-week highs, there still may be some life left in the shares.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 24, 2015)
at MarketWatch.com (Feb 23, 2015)
at CNBC.com (Feb 4, 2015)
at MarketWatch.com (Feb 2, 2015)
at Nasdaq.com (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs